Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-31T16:59:43.116Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of corticosteroids for cancer-related fatigue: A pilot randomized placebo-controlled trial of advanced cancer patients

Published online by Cambridge University Press:  05 November 2014

Kenji Eguchi ,
Michitaka Honda ,
Tatusji Kataoka ,
Taketo Mukouyama ,
Satoru Tsuneto ,
Junichi Sakamoto ,
Koji Oba  and
Shigetoyo Saji
Kenji Eguchi
Affiliation:
Department of Oncology, Teikyo University, Tokyo, Japan
Michitaka Honda*
Affiliation:
Department of Gastroenterological Surgery, Cancer Institute, Ariake Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
Tatusji Kataoka
Affiliation:
Ginza Namikidori Clinic, Tokyo, Japan
Taketo Mukouyama
Affiliation:
Department of Cancer Palliative Therapy, Cancer Institute, Ariake Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan
Satoru Tsuneto
Affiliation:
Department of Palliative Medicine, Osaka University, Osaka, Japan
Junichi Sakamoto
Affiliation:
Tokai Central Hospital, Kakamigahara, Japan
Koji Oba
Affiliation:
Translational Research and Clinical Trial Center, Hokkaido University, Sapporo, Hokkaido, Japan
Shigetoyo Saji
Affiliation:
Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan
*
Address correspondence and reprint requests to: Michitaka Honda, Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan. E-Mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Cancer-related fatigue (CRF) is a common and one of the most important issues in palliative medicine, and it has been demonstrated to have a significant impact on patient quality of life (QoL). The present pilot randomized controlled study evaluated the efficacy and toxicity of methylprednisolone (MP) for CRF in advanced cancer patients.

Method:

Our study was planned as a randomized, double-blind, multicenter, placebo-controlled trial. Patients were randomly assigned to an MP group, who received 32 mg/day of MP orally for 7 days, and a placebo group. The primary endpoint was an improvement in visual analog scale (VAS) score for fatigue from baseline to day 7. The secondary endpoints were improvements in appetite loss and QoL as well as evaluating the safety of corticosteroids as palliative therapy.

Results:

It was not possible to complete patient registration. In total, 35 patients were randomly assigned to an MP group (n = 18) and a placebo group (n = 17). The mean changes in VAS score for fatigue were –9.06 in the placebo group and –1.56 in the MP group, and for appetite loss –6.44 in the placebo group and –8.06 in the MP group. In addition, there was no evidence that methylprednisolone improved appetite loss or QoL compared to placebo. The incidence of adverse effects was not greater in the MP group.

Significant of Result:

We conclude that our sample size was too small to prove the efficacy of methylprednisolone in improving fatigue. Our results were reported as a pilot study performed to support a subsequent larger trial.

Keywords

Cancer-related fatigueCorticosteroidsMethylprednisolonePalliative care
Type
Original Articles
Information
Palliative & Supportive Care , Volume 13 , Issue 5 , October 2015 , pp. 1301 - 1308
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Andrykowski, M.A., Schmidt, J.E., Salsman, J.M., et al. (2005). Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer. Journal of Clinical Oncology, 23(27), 6613–6622.Google Scholar
Armes, J., Chalder, T., Addington-Hall, J., et al. (2007). A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue. Cancer, 110(6), 1385–1395.Google Scholar
Bruera, E., Kuehn, N., Miller, M.J., et al. (1991). The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. Journal of Palliative Care, 7(2), 6–9.Google Scholar
Bruera, E., Driver, L., Barnes, E.A., et al. (2003). Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. Journal of Clinical Oncology, 21(23), 4439–4443.Google Scholar
Bruera, E., Yennurajalingam, S., Palmer, J.L., et al. (2013). Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: A randomized, placebo-controlled, phase II trial. Journal of Clinical Oncology, 31(19), 2421–2427.Google Scholar
Campos, M.P., Hassan, B.J., Riechelmann, R., et al. (2011). Cancer-related fatigue: A review. Revista da Associação Médica Brasileira, 57(2), 211–219.Google Scholar
Cella, D., Davis, K., Breitbart, W., et al. (2001). Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 19(14), 3385–3391.Google Scholar
Chang, V.T., Hwang, S.S. & Feuerman, M. (2000). Validation of the Edmonton Symptom Assessment Scale. Cancer, 88(9), 2164–2171.Google Scholar
Debb, S.M., Arnold, B., Perez, B., et al. (2011). Validation of the FACT–Gastric cancer quality of life questionnaire for use in Spanish-speaking countries. Psycho-Oncology, 20(1), 19–27.Google Scholar
Esquerdo, G., Llorca, C., Cervera, J.M., et al. (2011). Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia: Relationship between variation in three fatigue-specific quality-of-life questionnaire scores and change in haemoglobin level. Clinical & Translational Oncology, 13(5), 341–347.Google Scholar
FACIT.org (2010). Functional Assessment of Chronic Illness Therapy. Available at www.facit.org.Google Scholar
Fernandes, R., Stone, P., Andrews, P., et al. (2006). Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: Evaluation of diagnostic criteria for cancer-related fatigue. Journal of Pain and Symptom Management, 32(3), 245–254.Google Scholar
Groenvold, M., Petersen, M.A., Aaronson, N.K., et al. (2006). The development of the EORTC QLQ–C15–PAL: A shortened questionnaire for cancer patients in palliative care. European Journal of Cancer, 42(1), 55–64.Google Scholar
Johnson, R.L., Block, I., Gold, M.A., et al. (2010). Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psycho-Oncology, 19(9), 955–958.Google Scholar
Kurihara, M., Shimizu, H., Tsuboi, K., et al. (1999). Development of quality of life questionnaire in Japan: Quality of life assessment of cancer patients receiving chemotherapy. Psycho-Oncology, 8(4), 355–363.Google Scholar
Levy, M.H., Adolph, M.D., Back, A., et al. (2012). Palliative care. Journal of the Nationall Comprehensive Cancer Network, 10(10), 1284–1309.Google Scholar
Mendoza, T.R., Wang, X.S., Cleeland, C.S., et al. (1999). The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer, 85(5), 1186–1196.Google Scholar
Minton, O., Richardson, A., Sharpe, M., et al. (2010). Drug therapy for the management of cancer-related fatigue. The Cochrane Database of Systematic Reviews, (7), CD006704.Google Scholar
Revicki, D.A., Stull, D., Vernon, M., et al. (2012). Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials. Quality of Life Research, 21(2), 311–321.Google Scholar
Sarhill, N., Walsh, D., Nelson, K.A., et al. (2001). Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study. The American Journal of Hospice & Palliative Care, 18(3), 187–192.Google Scholar
Schneider, C.M., Hsieh, C.C., Sprod, L.K., et al. (2007). Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer, 110(4), 918–925.Google Scholar
Wewers, M.E. & Lowe, N.K. (1990). A critical review of visual analogue scales in the measurement of clinical phenomena. Research in Nursing & Health, 13(4), 227–236.Google Scholar
Yeh, E.T., Lau, S.C., Su, W.J., et al. (2011). An examination of cancer-related fatigue through proposed diagnostic criteria in a sample of cancer patients in Taiwan. BMC Cancer, 11, 387.Google Scholar
Yennurajalingam, S., Frisbee-Hume, S., Palmer, J.L., et al. (2013). Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology, 31(25), 3076–3082.Google Scholar